Acción APLM APOLLOMICS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Apollomics, Inc.

Acciones

APLM

KYG0411D1079

Mercado cerrado - Nasdaq
Otros sitios de cotización
 22:30:00 21/06/2024 		Varia. Cinco días. Varia. 1 de enero.
0,2046 USD +4,76 % Gráfico intradía de Apollomics, Inc. +1,79 % -78,80 %
04/06 Apollomics anuncia datos sobre vebreltinib en la Reunión Anual 2024 de la Sociedad Estadounidense de Oncología Clínica (Asco) CI
08/05 Apollomics, Inc. nombra a Robert (Bob) Lin miembro del consejo de administración CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology Annual Meeting
Apollomics : BIO 2024 Presentation
ASCO 2024: Efficacy and safety of the vebreltinib in previously treated, IDH mutant high grade glioma patients with PTPRZ1 MET FUsion GENe (FUGEN): a randomized, multicentre, open label, phase II/III trial
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Apollomics Announces Vebreltinib Data At the 2024 American Society of Clinical Oncology Annual Meeting
Apollomics Announces Presentation at the 2024 BIO International Convention
Apollomics Announces Presentation at the 2024 BIO International Convention
Apollomics Announces Private Placement Financing and Addition to Board of Directors
Apollomics Announces Private Placement Financing and Addition to Board of Directors
Apollomics, Inc. Appoints Robert Lin to the Board of Directors
Apollomics, Inc. announced that it has received $5.75 million in funding
Apollomics, Inc. announced that it expects to receive $5.75 million in funding
Apollomics : April 2024 Corporate Presentation
Avistone Biotechnology Co. Ltd. Receives Approval from the National Medical Products Administration of China for Vebrelinib (APL-101) for the Treatment of Gliomas with Met Fusion Gene
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Predicine, Inc. Announces Collaboration with Apollomics, Inc. to Develop Predicinecare as A Companion Diagnostic Assay in Lung Cancer
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Apollomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción APLM
  4. Noticias Apollomics, Inc.
  5. Otros idiomas